The Evaluation of the Maculopathy Using Dynamic Contrast-enhanced MRI in Patients with Proliferative Diabetic Retinopathy

Article ID: e070721194588 Pages: 7

  • * (Excluding Mailing and Handling)

Abstract

Background: Dynamic Contrast-enhanced Magnetic Resonance Imaging (DCE-MRI) technique could not only quantify blood-retinal barrier (BRB) breakdown leading to macular edema associated with diabetes, but also provide a two-dimensional imaging method that is not interfered by refracting media.

Objective: The current study was aimed to evaluate the macular change in the patients with diabetic retinopathy using DCE-MRI technique.

Methods: Twenty patients with Diabetic Retinopathy (DR) and 20 Normal Controls (NC) were included. The fast spoiled gradient echo sequence was used to perform dynamic contrast T1WI enhancement on 3.0T MR system. The macular region, optic papila and nasal retina were performed with quantitative DCE-MRI evaluation using Omni-Kinetics software.

Results: The maximal concentration, the area under the concentration-time curve (AUCconcentration-time) and maximal slope of macular region were significantly higher in DR [0.270(0.03,1.20)mmol/ 100ml, 2.71(0.04,9.91) mmol*min and 0.38(0.06,3.18) mmol/min, respectively] than that [0.169(0.03,0.72) mmol/1.25(0.13,10.41) mmol*min and 0.245(0.06,1.34) mmol/min] in NC (U value = 515.00 and P value = 0.080, U value = 433.00 and P value = 0.000, and U value = 563.00 and P value = 0.023, respectively). The receiver operating characteristic curve (ROC) analysis demonstrated that the area under AUCconcentration-time was 0.729±0.058 with the cut-off value 1.479 mmol*min (sensitivity 80.00% and specificity 62.50%) for macular region.

Conclusion: The quantitative DCE-MRI technique could be used to evaluate the maculopathy associated with diabetic retinopathy.

Keywords: Diabetic retinopathy, magnetic resonance imaging, macula lutea retinae, optic papilla, BRB, neonatal control.

Graphical Abstract

[1]
Yau JW, Rogers SL, Kawasaki R, et al. Global prevalence and major risk factors of diabetic retinopathy. Diabetes Care 2012; 35(3): 556-64.
[http://dx.doi.org/10.2337/dc11-1909] [PMID: 22301125]
[2]
Bandello F, Battaglia Parodi M, Lanzetta P, et al. Diabetic macular edema. Dev Ophthalmol 2010; 47: 73-110.
[http://dx.doi.org/10.1159/000320075] [PMID: 20703045]
[3]
Browning DJ, Glassman AR, Aiello LP, et al. Relationship between optical coherence tomography-measured central retinal thickness and visual acuity in diabetic macular edema. Ophthalmology 2007; 114(3): 525-36.
[http://dx.doi.org/10.1016/j.ophtha.2006.06.052] [PMID: 17123615]
[4]
Gardner TW, Larsen M, Girach A, Zhi X, Protein Kinase CDRSSG. Diabetic macular oedema and visual loss: relationship to location, severity and duration. Acta Ophthalmol 2009; 87(7): 709-13.
[http://dx.doi.org/10.1111/j.1755-3768.2009.01545.x] [PMID: 19817721]
[5]
Sander B, Larsen M, Engler C, Moldow B, Lund-Andersen H. Diabetic macular oedema: The effect of photocoagulation on fluorescein transport across the blood-retinal barrier. Br J Ophthalmol 2002; 86(10): 1139-42.
[http://dx.doi.org/10.1136/bjo.86.10.1139] [PMID: 12234895]
[6]
Manfré L, Midiri M, Giuffré G, et al. Blood-ocular barrier damage: Use of contrast-enhanced MRI. Eur Radiol 1997; 7(1): 110-4.
[http://dx.doi.org/10.1007/s003300050121] [PMID: 9000410]
[7]
Trick GL, Liggett J, Levy J, et al. Dynamic contrast enhanced MRI in patients with diabetic macular edema: Initial results. Exp Eye Res 2005; 81(1): 97-102.
[http://dx.doi.org/10.1016/j.exer.2005.01.015] [PMID: 15978260]
[8]
Gadian DG, Payne JA, Bryant DJ, Young IR, Carr DH, Bydder GM. Gadolinium-DTPA as a contrast agent in MR imaging theoretical projections and practical observations. J Comput Assist Tomogr 1985; 9(2): 242-51.
[http://dx.doi.org/10.1097/00004728-198503000-00003] [PMID: 3973145]
[9]
Wilkinson CP, Ferris FL III, Klein RE, et al. Proposed international clinical diabetic retinopathy and diabetic macular edema disease severity scales. Ophthalmology 2003; 110(9): 1677-82.
[http://dx.doi.org/10.1016/S0161-6420(03)00475-5] [PMID: 13129861]
[10]
Chen Z, Chen X, Liu M, Liu S, Ma L, Yu S. Volume expansion of periaqueductal gray in episodic migraine: A pilot MRI structural imaging study. J Headache Pain 2017; 18(1): 83.
[http://dx.doi.org/10.1186/s10194-017-0797-z] [PMID: 28808987]
[11]
Qaum T, Xu Q, Joussen AM, et al. VEGF-initiated blood-retinal barrier breakdown in early diabetes. Invest Ophthalmol Vis Sci 2001; 42(10): 2408-13.
[PMID: 11527957]
[12]
Tan GS, Cheung N, Simó R, Cheung GC, Wong TY. Diabetic macular oedema. Lancet Diabetes Endocrinol 2017; 5(2): 143-55.
[http://dx.doi.org/10.1016/S2213-8587(16)30052-3] [PMID: 27496796]
[13]
Giebel SJ, Menicucci G, McGuire PG, Das A. Matrix metalloproteinases in early diabetic retinopathy and their role in alteration of the blood-retinal barrier. Lab Invest 2005; 85(5): 597-607.
[http://dx.doi.org/10.1038/labinvest.3700251] [PMID: 15711567]
[14]
Peng Q, Zhang Y, Nateras OS, van Osch MJ, Duong TQ. MRI of blood flow of the human retina. Magn Reson Med 2011; 65(6): 1768-75.
[http://dx.doi.org/10.1002/mrm.22763] [PMID: 21590806]
[15]
Duong TQ. Magnetic resonance imaging of the retina: From mice to men. Magn Reson Med 2014; 71(4): 1526-30.
[http://dx.doi.org/10.1002/mrm.24797] [PMID: 23716429]
[16]
Murakami T, Yoshimura N. Structural changes in individual retinal layers in diabetic macular edema. J Diabetes Res 2013; 2013: 920713.
[http://dx.doi.org/10.1155/2013/920713] [PMID: 24073417]
[17]
Hassan SS, Bong DB, Premsenthil M. Detection of neovascularization in diabetic retinopathy. J Digit Imaging 2012; 25(3): 437-44.
[http://dx.doi.org/10.1007/s10278-011-9418-6] [PMID: 21901535]
[18]
Berkowitz BA, Roberts R, Penn JS, Gradianu M. High-resolution manganese-enhanced MRI of experimental retinopathy of prematurity. Invest Ophthalmol Vis Sci 2007; 48(10): 4733-40.
[http://dx.doi.org/10.1167/iovs.06-1516] [PMID: 17898298]
[19]
Berkowitz BA, Bissig D, Bergman D, Bercea E, Kasturi VK, Roberts R. Intraretinal calcium channels and retinal morbidity in experimental retinopathy of prematurity. Mol Vis 2011; 17: 2516-26.
[PMID: 21976962]
[20]
Das R, Spence G, Hogg RE, Stevenson M, Chakravarthy U. Disorganization of inner retina and outer retinal morphology in diabetic macular edema. JAMA Ophthalmol 2018; 136(2): 202-8.
[http://dx.doi.org/10.1001/jamaophthalmol.2017.6256] [PMID: 29327033]
[21]
Schur RM, Sheng L, Sahu B, et al. Manganese-enhanced MRI for preclinical evaluation of retinal degeneration treatments. Invest Ophthalmol Vis Sci 2015; 56(8): 4936-42.
[http://dx.doi.org/10.1167/iovs.15-16522] [PMID: 26225634]
[22]
Kim JT, Lee DH, Joe SG, Kim JG, Yoon YH. Changes in choroidal thickness in relation to the severity of retinopathy and macular edema in type 2 diabetic patients. Invest Ophthalmol Vis Sci 2013; 54(5): 3378-84.
[http://dx.doi.org/10.1167/iovs.12-11503] [PMID: 23611988]